Meeting
2017 ASCO Annual Meeting
The safety and early efficacy of high-dose ipilimumab (IPI) and the combination nivolumab plus ipilimumab (NIVO + IPI) in patients (pts) with uveal melanoma (UM).
Authors
Sapna Pradyuman Patel
The University of Texas MD Anderson Cancer Center, Houston, TX
Sapna Pradyuman Patel , Isabella Claudia Glitza , Adi Diab , Rodabe Navroze Amaria , Michael A. Davies , Patrick Hwu , Hussein Abdul-Hassan Tawbi , Wen-Jen Hwu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT01585194
Citation
J Clin Oncol 35, 2017 (suppl; abstr 9554)
DOI
10.1200/JCO.2017.35.15_suppl.9554
Abstract #
9554
Poster Bd #
162
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Safety and efficacy of combined melphalan percutaneous hepatic perfusion (M-PHP) and ipilimumab plus nivolumab (IPI+NIVO) in metastasized uveal melanoma (mUM): First results of the phase Ib part of the CHOPIN trial.
First Author: Thaïs M.L. Tong
Poster
2019 ASCO Annual Meeting
Phase II study of ipilimumab and nivolumab (ipi/nivo) in metastatic uveal melanoma (UM).
First Author: Meredith Pelster
Poster
2021 ASCO Annual Meeting
Phase Ib/randomized phase II study combining hepatic percutaneous perfusion with ipilimumab plus nivolumab in advanced uveal melanoma: The CHOPIN trial.
First Author: Thaïs M.L. Tong
Poster
2015 ASCO Annual Meeting
Preliminary safety and activity of nivolumab and its combination with ipilimumab in recurrent glioblastoma (GBM): CHECKMATE-143.
First Author: John H. Sampson